Tivic Health Reports Q1 Non-GAAP Loss of $2.23 per Share

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 17 hours ago

0mins

VBIO-5.48%

Should l Buy VBIO?

Source: seekingalpha

Financial Performance: Tivic Health Systems reported a Q1 2026 non-GAAP loss per share of $2.23, with a net loss of $6.2 million, indicating significant financial pressure amid market competition.
Operating Expenses: The company's operating expenses reached $5.6 million in Q1, reflecting an increase compared to the previous year, which may impact future profitability and cash flow management.
Market Opportunity: Tivic Health outlines a significant opportunity in the $20 billion oncology market, demonstrating confidence in future growth following its strategic transformation.
Funding Support: Valion Bio Inc. aims to complete GMP validation for Entolimod by the end of 2026, backed by NIAID funding, showcasing the company's proactive positioning in the biopharmaceutical sector.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy VBIO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on VBIO

Wall Street analysts forecast VBIO stock price to rise

0 Analyst Rating

0 Buy

0 Hold

0 Sell

Current: 0.931

Low

Averages

High

Current: 0.931

Low

Averages

High

No data

About VBIO

Valion Bio, Inc., formerly Tivic Health Systems, Inc., is a late-stage immunotherapeutics company. The Company offers Entolimod, which is a drug used to treat acute radiation syndrome (ARS). Entolimod is a toll-like receptor 5 (TLR5) agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. Its pipeline also includes Entolimod to treat neutropenia and lymphocyte exhaustion, as well as Entolasta, an immunologically optimized variant of Entolimod for chronic applications. Its subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that is based in San Antonio, Texas. It offers upstream and downstream process development and optimization; analytical testing, assay development, and qualification; quality control and stability testing; microbial and mammalian expression systems; technology transfer and program management services.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Valion Bio Reports Q1 2026 Earnings and Strategic Outlook

1 day agoseekingalpha

Financial Overview: Valion Bio reported a net loss of $6.2 million for Q1 2026, significantly up from a $1.5 million loss a year earlier, reflecting high operating costs associated with business expansion, although the loss per share improved from $2.52 to $2.23.
R&D Spending Increase: Research and development expenses for the quarter reached $1.9 million, a substantial rise from $0.3 million in Q1 2025, indicating the company's ongoing commitment to accelerating the clinical development of Entolimod.
Strategic Plans and Risks: Management highlighted future strategic initiatives, including initiating physician-sponsored studies for neutropenia in the second half of 2026, while also addressing financing and listing risks that could impact operational capabilities and market performance.
Cash Flow Status: As of March 31, 2026, Valion Bio had cash and cash equivalents of $7.2 million, down from $12.6 million at the end of 2025, with $5 million used in operating activities during Q1, indicating pressure on the company's financial management.